- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01025856
Combined Nutritional and Exercise Strategies to Reduce Liver Fat Content in Patients With Type 2 Diabetes
December 3, 2012 updated by: rivellese angela, Federico II University
The aim of this study will be to evaluate in patients with type 2 diabetes the effects on liver fat of an intervention with a diet relatively rich in CHO/rich in fibre/low GI or a diet rich in MUFA, either combined or not with a structured program of physical exercise, with emphasis on mechanisms possibly underlining these effects, namely changes in postprandial triglyceride-rich lipoproteins, body fat distribution, insulin sensitivity, oxidative stress and inflammation, adipose tissue lipolytic activities, aerobic capacity and endothelial function.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and postmenopausal women
- Age 35-65 years
- BMI 27- 34 kg/m2
- HbA1c <8%
- Fasting plasma cholesterol <250 mg/dl
- Fasting plasma triglycerides <300 mg/dl
Exclusion Criteria:
- Hypolipidemic drugs
- Plasma creatinine >1.7 mg/dl transaminases > 2 norma values
- Ischemic heart disease or positive treadmill stress test
- High intensity regular physical activity
- Any disease or chronic or/and acute condition contraindicating physical activity(anaemia, and infectious, neoplastic, neurological and osteoarticular diseases).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: high fibre/low glycemic index diet - P A
patients will follow for two months a diet high fibre/low glycemic index without physical activity program
|
Patients will follow for two months a high fibre/low glycemic index diet without a physical activity program.
|
Active Comparator: Rich in MUFA diet - PA
Patients will follow for two months a rich in MUFA diet without a physical activity program.
|
The patients will follow a rich in MUFA diet without a physical activity program.
|
Active Comparator: high fibre/low glycemic index diet+PA
Patients will follow for two months a high fibre and low glycemic index diet associated with a physical activity program.
|
patients will follow for two months a high fibre/ low glycemic index diet with a physical activity program.
|
Active Comparator: Rich in MUFA diet+PA
Patients will follow for 2 months a rich in MUFA diet with a physical activity program.
|
Patients will follow for two months a rich in MUFA diet with a physical activity program.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Liver fat content
Time Frame: 0 and 8 weeks
|
0 and 8 weeks
|
postprandial lipids metabolism
Time Frame: 0 and 8 weeks
|
0 and 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
changes in body fat distribution
Time Frame: 0 and 8 weeks
|
0 and 8 weeks
|
oxidative stress and inflammation
Time Frame: 0 and 8 weeks
|
0 and 8 weeks
|
adipose tissue lipolytic activities
Time Frame: 0 and 8 weeks
|
0 and 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Bozzetto L, Costabile G, Luongo D, Naviglio D, Cicala V, Piantadosi C, Patti L, Cipriano P, Annuzzi G, Rivellese AA. Reduction in liver fat by dietary MUFA in type 2 diabetes is helped by enhanced hepatic fat oxidation. Diabetologia. 2016 Dec;59(12):2697-2701. doi: 10.1007/s00125-016-4110-5. Epub 2016 Sep 20.
- Bozzetto L, Annuzzi G, Costabile G, Costagliola L, Giorgini M, Alderisio A, Strazzullo A, Patti L, Cipriano P, Mangione A, Vitelli A, Vigorito C, Riccardi G, Rivellese AA. A CHO/fibre diet reduces and a MUFA diet increases postprandial lipaemia in type 2 diabetes: no supplementary effects of low-volume physical training. Acta Diabetol. 2014;51(3):385-93. doi: 10.1007/s00592-013-0522-6. Epub 2013 Oct 17.
- Bozzetto L, Prinster A, Annuzzi G, Costagliola L, Mangione A, Vitelli A, Mazzarella R, Longobardo M, Mancini M, Vigorito C, Riccardi G, Rivellese AA. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients. Diabetes Care. 2012 Jul;35(7):1429-35. doi: 10.2337/dc12-0033.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Actual)
September 1, 2011
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
December 2, 2009
First Submitted That Met QC Criteria
December 3, 2009
First Posted (Estimate)
December 4, 2009
Study Record Updates
Last Update Posted (Estimate)
December 5, 2012
Last Update Submitted That Met QC Criteria
December 3, 2012
Last Verified
December 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 46/09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on High fibre/low glycemic index diet-PA
-
University of TorontoSaskatchewan Pulse Growers; Pulse CanadaCompleted
-
Universidad Autonoma de Baja CaliforniaTerminated
-
National University of SingaporeActive, not recruitingPersonalized NutritionSingapore
-
University of TorontoCompletedCardiovascular Disease | Type 2 DiabetesCanada
-
University of TorontoCanadian Institutes of Health Research (CIHR)Completed
-
University of SaskatchewanHeart and Stroke Foundation of CanadaCompletedHypercholesterolemiaCanada
-
Rio de Janeiro State UniversityCompleted
-
University of NottinghamRecruitingFatty Liver | Nutritional and Metabolic DiseaseUnited Kingdom
-
Azienda Ospedaliera Specializzata in Gastroenterologia...Completed
-
Hospital de Clinicas de Porto AlegreUnknownKidney Failure, Chronic | End-Stage Renal DiseaseBrazil